Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL334991 | 0.98 | OPRM1 (0.49) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| SCHEMBL373667 | 0.98 | OPRM1 (0.48) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL144177 | 0.95 | OPRM1 (0.50) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| Bromide SCHEMBL8961491 | 0.95 | OPRM1 (0.47) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| SCHEMBL2795989 | 0.91 | OPRM1 (0.44) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| SCHEMBL29151407 | 0.89 | OPRM1 (0.49) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| SCHEMBL9329761 | 0.87 | HTT (0.53) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| SCHEMBL8021687 | 0.87 | TSHR (0.59) | OPRM1TSHRALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL16104361 | 0.87 | CARM1 (0.55) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| SCHEMBL17195397 | 0.87 | HTT (0.56) | OPRM1OPRD1OPRK1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1000 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190083423-A1 | METHOD OF REDUCING NEURONAL CELL DEATH WITH HALOALKYLAMINES | THE UNIVERSITY OF MONTANA (US) | 2019-03-21 | — | — | US | claimed |
| US-20160220515-A1 | METHOD OF REDUCING NEURONAL CELL DEATH WITH HALOALKYLAMINES | THE UNIVERSITY OF MONTANA | 2016-08-04 | — | — | US | claimed |
| EP-3041465-A2 | METHOD OF REDUCING NEURONAL CELL DEATH WITH HALOALKYLAMINES | The University Of Montana (US) | 2016-07-13 | — | — | EP | claimed |
| CN-105530924-A | Method for reducing neuronal cell death with haloalkylamines | THE UNIV OF MONTANA | 2016-04-27 | — | — | CN | claimed |
| WO-2015035308-A2 | METHOD OF REDUCING NEURONAL CELL DEATH WITH HALOALKYLAMINES | THE UNIVERSITY OF MONTANA (US) | 2015-03-12 | — | — | WO | claimed |
| US-20130121923-A1 | Treatment of Male Sexual Dysfunction | PFIZER INC. (US) | 2013-05-16 | — | — | US | claimed |
| WO-2012162364-A1 | PHENOXYBENZAMINE FOR PAIN | NEW YORK MEDICAL COLLEGE (US) | 2012-11-29 | — | — | WO | claimed |
| US-20110107442-A1 | Treatment of Male Sexual Dysfunction | IXCHELSIS LIMITED (GB) | 2011-05-05 | — | — | US | claimed |
| US-20090175793-A1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER INC. | 2009-07-09 | — | — | US | claimed |
| EP-1109542-A4 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-03-26 | — | — | EP | claimed |
| EP-0278158-A2 | Renin inhibitors containing phenylalanyl-histidine replacements | MERCK & CO. INC. (US) | 1988-08-17 | — | — | EP | claimed |
| EP-0273696-A2 | Renin inhibitors containing histidine replacements | MERCK & CO. INC. (US) | 1988-07-06 | — | — | EP | claimed |
| WO-1988004179-A1 | COMBINATIONS OF RENAL VASODILATORS AND alpha1-ADRENERGIC OR GANGLIONIC BLOCKING AGENTS AND METHODS FOR TREATING DISEASES | NEW YORK MEDICAL COLLEGE (US) | 1988-06-16 | — | — | WO | claimed |
| US-4749686-A | Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases | NEW YORK MEDICAL COLLEGE (US) | 1988-06-07 | — | — | US | claimed |
| EP-0209897-A2 | Peptide enzyme inhibitors | MERCK & CO. INC. (US) | 1987-01-28 | — | — | EP | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |
| EP-0157409-A2 | Renin inhibitors containing 2-substituted statine | MERCK & CO. INC. (US) | 1985-10-09 | — | — | EP | claimed |
| EP-0156318-A2 | C-terminal amide cyclic renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0156322-A2 | Renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130121923-A1 | Treatment of Male Sexual Dysfunction | OXTR, AVPR1B, AVPR2 | OPRM1 61/4885OPRD1 26/4885OPRK1 103/4885 |
| US-20110107442-A1 | Treatment of Male Sexual Dysfunction | OXTR, AVPR1B, AVPR2 | OPRM1 61/4885OPRD1 26/4885OPRK1 103/4885 |
| US-20090175793-A1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | OXTR, AVPR1B, AVPR2 | OPRM1 61/4885OPRD1 26/4885OPRK1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.